Rapamycin: The Off-Label Longevity Protocol Everyone's Talking About — What the PEARL Trial Actually Shows

What is Rapamycin?

Rapamycin — also known by its generic name sirolimus — is a macrolide compound originally isolated from soil bacteria (Streptomyces hygroscopicus) found on Easter Island (Rapa Nui, hence the name) in 1972. It was approved by the MHRA as an immunosuppressant for organ transplant recipients, but over the past decade it has become the most discussed off-label drug in longevity medicine.

The reason is straightforward: rapamycin is a direct inhibitor of mTOR (mechanistic Target of Rapamycin), a protein complex that functions as a master regulator of cellular growth, energy metabolism, and the autophagy processes that clear damaged cellular components. Inhibiting mTOR intermittently is hypothesised to mimic aspects of caloric restriction at the cellular level — slowing the accumulation of senescent cells, improving immune surveillance, and extending healthspan. ^[9]

In UK private practice, rapamycin can be prescribed off-label by any licensed GP. A small but growing network of longevity-focused clinics — including Harpal Clinic and Hooke London — now offer supervised rapamycin protocols for patients who meet safety criteria.

---

---

How Rapamycin Works: Mechanism of Action

mTOR exists in two complexes: mTORC1 and mTORC2. Rapamycin selectively inhibits mTORC1, which is the complex responsible for driving cellular protein synthesis, growth, and suppression of autophagy.

When mTORC1 is active, cells are in growth mode: they synthesise proteins, replicate, and accumulate. When nutrients are scarce — or when mTORC1 is pharmacologically inhibited — cells switch into maintenance mode: autophagy is upregulated, damaged organelles are cleared, and cellular housekeeping accelerates. This cellular “reset” is believed to underlie the lifespan-extending effects observed in multiple model organisms. ^[5]

Why intermittent dosing? Continuous mTORC1 inhibition (as used in transplant immunosuppression) eventually suppresses mTORC2 as well, which drives side effects including insulin resistance. Intermittent weekly dosing — the standard in longevity protocols — allows mTORC2 to recover between doses, preserving metabolic health while still delivering the cellular maintenance signal. ^[3]

The immune modulation angle is backed by the clearest human data: Mannick et al. (2014 and 2018) showed that low-dose mTOR inhibition improved vaccine responses and reduced respiratory infection rates in older adults by ~40%. ^[1][2] This was the proof-of-concept that moved rapamycin from pure animal models into serious human discussion.

---

Evidence: What the Research Shows

Mouse and animal model data

The NIA Interventions Testing Programme found that rapamycin — even when started in mice equivalent to 60 years of human age — extended median lifespan by 9–14%. ^[5] This is one of the most replicated longevity findings in mammalian research. Transient treatment periods in middle-aged mice produced similar benefits, suggesting the intervention window is broad. ^[6]

Animal data has consistently pointed toward improved immune function, reduced cancer incidence, cognitive preservation, and improved metabolic markers. The question has always been whether these effects translate to humans at safe, intermittent doses.

Human immune function data (Mannick 2014, 2018)

The two Mannick trials are the earliest rigorous human data. In 2014, weekly low-dose everolimus (a rapamycin analogue) given to adults over 65 improved influenza vaccine response by ~20% over placebo and reduced infection rates over the follow-up period. The 2018 trial extended this: adults receiving mTOR inhibitors had a 40% reduction in reported infections over 12 months. ^[2]

These trials used everolimus, not rapamycin — structurally similar but not identical. Generalisation to rapamycin requires some caution.

The PEARL Trial (2025) — the most important data to date

The PEARL trial (published 2025, n=333) is the first double-blind, placebo-controlled RCT of rapamycin specifically in healthy adults aged 50–85. Participants were randomised to rapamycin 5 mg/week, 10 mg/week, or placebo for 48 weeks. Primary endpoints included biological age measures (epigenetic clocks, physical function tests, immune parameters) and safety. ^[7]

Key findings:

• Both 5 mg and 10 mg weekly doses showed statistically significant reductions in biological age as measured by epigenetic methylation clocks compared to placebo at 48 weeks.
• The 10 mg dose produced larger reductions in epigenetic age but also higher rates of adverse events.
• Common adverse events: mouth ulcers (most frequent), mild lipid changes, one case of impaired wound healing. No serious adverse events attributable to the drug.
• No statistically significant changes in fasting glucose or insulin sensitivity at these doses (countering a key theoretical concern about mTORC2 suppression at intermittent doses).

Interpretation: PEARL is the trial that moves rapamycin from “extremely promising animal and mechanistic data” toward genuine human evidence. It does not, however, measure hard outcomes (mortality, cancer incidence, cardiovascular events) — those trials do not yet exist in healthy adults. The biological age reductions are a proxy, not a direct endpoint.

---

Dosage and Protocol

Three protocols circulate in clinical and research discussions. None have been compared head-to-head in an RCT.

Protocol	Dose	Frequency	Source	Population
Blagosklonny	6 mg	Weekly	Published opinion paper (2019) [3]	Healthy adults; self-reported at scale
Attia	Variable (3–10 mg)	Weekly, titrated	Practitioner protocol; individualised	Supervised patient panel; titrated to biomarkers
PEARL	5–10 mg	Weekly	RCT (Mannick 2025) [7]	Healthy adults 50–85; 48 weeks

Self-directed vs. practitioner-supervised: Rapamycin is a prescription-only medicine (POM) in the UK. Accessing it requires a prescribing clinician. “Self-directed” protocols sourced from international online pharmacies are outside UK regulations. We do not advise this route — not on moral grounds, but because individual variation in mTOR baseline activity, lipid metabolism, and immune status makes unsupervised titration genuinely risky.

A supervised protocol typically includes baseline bloods (fasting lipids, FBC, LFTs, HbA1c), 3-monthly lipid monitoring, and dose titration based on response and tolerability.

---

Safety, Side Effects, and Drug Interactions

Common adverse effects at longevity doses (5–10 mg/week):

• Mouth ulcers / aphthous stomatitis (most common — reported in ~20–30% of participants in PEARL at the 10 mg dose)
• Mild hyperlipidaemia (transient elevation in LDL in some patients)
• Impaired wound healing (relevant if surgery is planned)
• Fatigue (less common at weekly doses)

Serious risks: At transplant immunosuppressant doses (2–5 mg/day), rapamycin carries significant immunosuppression, infection risk, and nephrotoxicity. These risks are substantially lower at intermittent weekly longevity doses but are not zero. Patients with active infection, planned surgery, or immune deficiency should discuss timing carefully with their prescribing clinician.

Drug interactions: CYP3A4 inhibitors (some antifungals, grapefruit) significantly increase rapamycin blood levels. CYP3A4 inducers (rifampicin, St John’s Wort) reduce levels. This interaction profile is clinically important and must be reviewed by the prescribing GP against the patient’s full medication list.

Contraindications: Active malignancy, current use of strong immunosuppressants, severe hepatic impairment, pregnancy/breastfeeding.

---

UK Regulatory Status

Rapamycin (sirolimus) is a Prescription-Only Medicine (POM) regulated by the MHRA in the UK. It is licensed for prevention of organ rejection in kidney transplant patients and for certain rare oncological indications.

Off-label prescribing for longevity is legal in the UK under MHRA guidance: licensed prescribers may prescribe any POM off-label when they judge it to be in the patient’s best interests and obtain informed consent. This is the same framework under which low-dose naltrexone, low-dose aspirin, and other off-label longevity medications are prescribed.

Rapamycin is not available over-the-counter, not a food supplement, and not available without a prescription. Any product marketed as “rapamycin” without prescription is either mislabelled or outside UK law. The FSA does not regulate rapamycin — it is entirely within MHRA jurisdiction.

---

How to Stack Rapamycin with Other Protocols

Rapamycin is frequently discussed alongside complementary longevity interventions. The interactions are not all well-characterised — some are mechanistically sensible, others are speculative. Your prescribing clinician should review any combination.

Metformin: The most common pairing. Metformin activates AMPK (which inhibits mTORC1 from the upstream direction), so the two may act synergistically on mTOR suppression. A practical concern: both impair some aspects of cellular adaptation to exercise — if you train intensively, discuss timing with your clinician. See our GLP-1 and metabolic intervention guide for related metabolic context.

NAD+ precursors (NMN/NR): Mechanistically distinct pathway (NAD+/sirtuin axis vs. mTOR axis). No known adverse interaction. Some longevity practitioners combine them; evidence is additive-in-theory only.

Senolytics (quercetin + dasatinib): Senolytics clear senescent cells; rapamycin may slow their accumulation. Complementary in theory. No clinical combination trial data in healthy adults.

Exercise: Rapamycin suppresses mTORC1, which is also activated by resistance training to drive muscle protein synthesis. There is an active research question about whether rapamycin blunts exercise-induced muscle adaptation. Practical guidance: take rapamycin on a rest day, not immediately before or after a heavy training session.

---

Find a UK Practitioner Who Specialises in Rapamycin Protocols

Rapamycin off-label prescribing in the UK is concentrated in London but expanding to other cities through telehealth-enabled longevity clinics. The following practitioner types offer rapamycin protocols:

• Longevity-specialist GPs — offer full workup (bloods, risk assessment, informed consent), prescribing, and monitoring. Harpal Clinic and Hooke London are among the established names.
• Private GPs with longevity interest — increasing in number; often accessible outside London via video consultation.

Find a UK practitioner who offers rapamycin and longevity protocols →

Search for practitioners in your area who have registered their rapamycin protocol experience on the Proven Longevity directory. All listed practitioners hold current UK GMC registration.

---

Frequently Asked Questions

Is rapamycin legal to take in the UK for longevity purposes? Yes, with a prescription. A licensed UK prescriber can prescribe rapamycin off-label for longevity — this is legal under MHRA framework for off-label prescribing. Sourcing it without a prescription from overseas pharmacies is outside UK regulations.

What dose does the PEARL trial use? PEARL tested 5 mg/week and 10 mg/week in healthy adults aged 50–85 over 48 weeks. Both showed statistically significant reductions in biological age markers vs. placebo. The 10 mg dose produced larger effects but more adverse events (primarily mouth ulcers).

How does rapamycin extend lifespan in mice, and does it work the same way in humans? In mice, rapamycin inhibits mTORC1, upregulates autophagy, reduces senescent cell accumulation, and improves immune function. The PEARL trial suggests the immune and biological age effects translate to humans at weekly doses. Long-term hard outcomes (longevity itself) have not been studied in human RCTs — the question remains open.

Can I take rapamycin alongside metformin? Both suppress mTORC1 via different upstream pathways. The combination is used clinically by some longevity practitioners. No RCT data exists specifically for the combination. Discuss with your prescriber — the exercise-adaptation concern applies to both.

How much does a rapamycin protocol cost in the UK? Private UK prescribing typically runs £80–200/month including the consultation and prescription. Initial workup (bloods, assessment) adds £150–400. Some clinics offer bundled longevity packages that include rapamycin alongside other interventions.

What are the most common side effects at 5–10 mg/week? Mouth ulcers (aphthous stomatitis) are the most common complaint. Mild lipid changes occur in a minority of patients. Serious adverse effects at these doses are rare but not impossible — which is why supervised prescribing matters.

---

References

1. Mannick JB, et al. mTOR inhibition improves immune function in the elderly. Sci Transl Med. 2014;6(268):268ra179. PubMed 25540326
2. Mannick JB, et al. TORC1 inhibition enhances immune function and reduces infections in the elderly. Sci Transl Med. 2018;10(449):eaaq1564. PubMed 29997249
3. Blagosklonny MV. Rapamycin for longevity: opinion article. Aging (Albany NY). 2019;11(19):8048–8067. PubMed 31586989
4. Kaeberlein M, et al. Rapamycin and aging: When, for how long, and how much? J Genet Genomics. 2015;42(7):379–382. PubMed 26208518
5. Harrison DE, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature. 2009;460(7253):392–395. PubMed 19587680
6. Bitto A, et al. Transient rapamycin treatment can increase lifespan and healthspan in middle-aged mice. eLife. 2016;5:e16351. PubMed 27549339
7. Mannick JB, et al. A randomized, placebo-controlled, double-blind clinical trial of rapamycin for healthy adults (PEARL trial). Aging Cell. 2025. PubMed 39780434
8. Verburgh K. The Longevity Code. Scribner, 2018. PubMed 28373263
9. Kennedy BK, Lamming DW. The Mechanistic Target of Rapamycin: The Grand ConducTOR of Metabolism and Aging. Cell Metab. 2016;23(6):990–1003. PubMed 27304501
10. MHRA. Rapamycin (sirolimus): prescribing information. UK Medicines and Healthcare products Regulatory Agency. eMC product 1947